MX2022006390A - Transducción de car y edición de genes mediante crispr combinadas de células nk a gran escala. - Google Patents

Transducción de car y edición de genes mediante crispr combinadas de células nk a gran escala.

Info

Publication number
MX2022006390A
MX2022006390A MX2022006390A MX2022006390A MX2022006390A MX 2022006390 A MX2022006390 A MX 2022006390A MX 2022006390 A MX2022006390 A MX 2022006390A MX 2022006390 A MX2022006390 A MX 2022006390A MX 2022006390 A MX2022006390 A MX 2022006390A
Authority
MX
Mexico
Prior art keywords
cells
gene editing
crispr gene
scale combined
combined car
Prior art date
Application number
MX2022006390A
Other languages
English (en)
Inventor
Katy Rezvani
May Daher
Rafet Basar
Costa David Marin
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2022006390A publication Critical patent/MX2022006390A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las modalidades de la descripción abarcan métodos y composiciones para producir células asesinas naturales (NK) modificadas. La descripción se refiere a procesos a gran escala para producir células NK que se modifican para tener alteración de la expresión de uno o más genes, tal como usar CRISPR, y también se modifican para expresar al menos un receptor de antígeno heterólogo. Las modalidades específicas incluyen parámetros particulares para el proceso.
MX2022006390A 2019-11-27 2020-11-25 Transducción de car y edición de genes mediante crispr combinadas de células nk a gran escala. MX2022006390A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962941134P 2019-11-27 2019-11-27
PCT/US2020/062372 WO2021108671A1 (en) 2019-11-27 2020-11-25 Large-scale combined car transduction and crispr gene editing of nk cells

Publications (1)

Publication Number Publication Date
MX2022006390A true MX2022006390A (es) 2022-09-12

Family

ID=76129923

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006390A MX2022006390A (es) 2019-11-27 2020-11-25 Transducción de car y edición de genes mediante crispr combinadas de células nk a gran escala.

Country Status (10)

Country Link
US (1) US20220389383A1 (es)
EP (1) EP4065140A4 (es)
JP (1) JP2023504043A (es)
KR (1) KR20220106803A (es)
CN (1) CN115989034A (es)
AU (1) AU2020393914A1 (es)
BR (1) BR112022010225A2 (es)
CA (1) CA3163258A1 (es)
MX (1) MX2022006390A (es)
WO (1) WO2021108671A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310716A (en) * 2021-08-10 2024-04-01 Gamida Cell Ltd Transgenic NK cells, their production and use
WO2023062113A1 (en) * 2021-10-15 2023-04-20 Miltenyi Biotec B.V. & Co. KG Method for the generation of genetically modified nk cells
WO2023178196A2 (en) * 2022-03-15 2023-09-21 The General Hospital Corporation Ecm receptor modulation in nk cell therapy
CN115820645B (zh) * 2022-11-28 2023-09-22 上海恩凯细胞技术有限公司 制备沉默nkg2a基因的nk细胞的方法及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3612210A4 (en) * 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
US20210230548A1 (en) * 2018-05-03 2021-07-29 Board Of Regents, The University Of Texas System Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade

Also Published As

Publication number Publication date
EP4065140A1 (en) 2022-10-05
BR112022010225A2 (pt) 2022-09-06
WO2021108671A1 (en) 2021-06-03
EP4065140A4 (en) 2024-02-21
AU2020393914A1 (en) 2022-06-16
KR20220106803A (ko) 2022-07-29
US20220389383A1 (en) 2022-12-08
JP2023504043A (ja) 2023-02-01
CA3163258A1 (en) 2021-06-03
CN115989034A (zh) 2023-04-18

Similar Documents

Publication Publication Date Title
MX2022006390A (es) Transducción de car y edición de genes mediante crispr combinadas de células nk a gran escala.
PH12019502529A1 (en) Materials and methods for engineering cells and uses thereof in immuno-oncology
PH12018500965A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
MX2020013357A (es) Polimerasas, composiciones y metodos de uso.
MX2020013347A (es) Polimerasas, composiciones y metodos de uso.
WO2016201047A8 (en) Crispr/cas-related methods and compositions for improving transplantation
MX2021001523A (es) Procesos para generar células modificadas y composiciones de las mismas.
TN2017000431A1 (en) Production of oversized adeno-associated vectors
PH12020550039A1 (en) Sialyltransferases and their use in producing sialylated oligosaccharides
WO2015108993A8 (en) Mutagenesis methods
MX2019007765A (es) Mutantes de algas de productividad elevada que tienen antena fotosintetica reducida.
WO2017051347A3 (en) Cells and method of cell culture
WO2019232409A9 (en) Methods for genome editing and activation of cells
MX2020013017A (es) Materiales y metodos para tratar cancer.
EP3929285A3 (en) Methods of reducing odor
WO2016007570A3 (en) Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
MX2018015298A (es) Metodo para estabilizar proteinas.
CR20220101A (es) Composiciones y métodos para modificar una característica vegetal sin modificar el genoma vegetal
SG11201903254PA (en) Undifferentiated stem cell-removing agent, and method for removing undifferentiated stem cells
MX2017011220A (es) Metodos para hacer celulas madre neurales y usos de las mismas.
MX2021004993A (es) Materiales y metodos para tratar cancer.
MX2021013223A (es) Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
JOP20200250A1 (ar) تركيبات aav، وطرق تحضيرها وطرق الاستخدام
WO2015157431A3 (en) Selective advantage in fermentation
MX2018015234A (es) Métodos para mejorar la transformación genética de sorgo.